These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15932834)

  • 1. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.
    Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ
    Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combined hormonal contraception in cycles artificially extended].
    Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
    Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of estrogen-withdrawal headache with extended transdermal contraception.
    LaGuardia KD; Fisher AC; Bainbridge JD; LoCoco JM; Friedman AJ
    Fertil Steril; 2005 Jun; 83(6):1875-7. PubMed ID: 15950671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
    Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
    Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
    Creasy GW; Fisher AC; Hall N; Shangold GA
    J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.
    Devineni D; Skee D; Vaccaro N; Massarella J; Janssens L; LaGuardia KD; Leung AT
    J Clin Pharmacol; 2007 Apr; 47(4):497-509. PubMed ID: 17389559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
    Henzl MR; Loomba PK
    J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
    Coffee AL; Sulak PJ; Kuehl TJ
    Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical study of transdermal contraceptive patch in Thai adolescence women.
    Piyasirisilp R; Taneepanichskul S
    J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A look at the long-term safety of an extended-regimen OC.
    Davis MG; Reape KZ; Hait H
    J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal contraception.
    Creasy GW; Abrams LS; Fisher AC
    Semin Reprod Med; 2001 Dec; 19(4):373-80. PubMed ID: 11727179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oral versus transdermal steroidal contraceptives on androgenic markers.
    White T; Jain JK; Stanczyk FZ
    Am J Obstet Gynecol; 2005 Jun; 192(6):2055-9. PubMed ID: 15970897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen.
    Sulak PJ; Kuehl TJ; Coffee A; Willis S
    Am J Obstet Gynecol; 2006 Oct; 195(4):935-41. PubMed ID: 16647684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra).
    Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit
    J Fam Plann Reprod Health Care; 2004 Jan; 30(1):43-5. PubMed ID: 15006313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical study of transdermal contraceptive patch in Thai women.
    Suwanmalee O; Taneepanichskul S
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S1-4. PubMed ID: 17726805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?
    Edelman AB; Koontz SL; Nichols MD; Jensen JT
    Obstet Gynecol; 2006 Mar; 107(3):657-65. PubMed ID: 16507938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study.
    Weisberg F; Bouchard C; Moreau M; Audet MC; Mawdsley S; Dattani D; Dinniwell J; Horbay GL;
    J Obstet Gynaecol Can; 2005 Apr; 27(4):350-9. PubMed ID: 15937609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive.
    Westhoff C; Osborne LM; Schafer JE; Morroni C
    Obstet Gynecol; 2005 Jul; 106(1):89-96. PubMed ID: 15994622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.